World-renowned breast cancer researcher gives Presidential Distinguished Lecture
President Cigarroa welcomed 2006 invited lecturer Angela Brodie, M.D., of the University of Maryland Greenebaum Cancer Center. Dr. Brodie discussed compounds called selective aromatase inhibitors that inhibit the hormone estrogen. Her lab was the first to report this class of compounds as a possible new treatment for breast cancer.
Three U.S. Food & Drug Administration-approved aromatase inhibitors are available today. The first to be commercially available, 4-OHA, was developed by Ciba-Geigy, now Novartis. It debuted on the market in 1994.
The Presidential Distinguished Lecturers have included: 2002, Dr. Judah Folkman; 2003, Dr. Thomas Starzl; 2004, Dr. Robert Langer; 2005, Dr. Denton Cooley; and 2006, Dr. Angela Brodie.
The goal of the annual event is to inspire Health Science Center students, one of whom will make a discovery like Dr. Brodie’s that could change the world and help alleviate human suffering. Dr. Cigarroa commented that one day, that person will return to the Health Science Center campus to stand on stage as the Presidential Distinguished Lecturer.
UT Health Science Center
© 2002 - 2015 UTHSCSA
Links provided from UTHSCSA pages to other websites do not constitute or imply an endorsement of those sites, their content, or products and services associated with those sites.